473923-56-7

Basic information

• Product Name: 3-HYDROXYMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: Di-tert-butyl morpholine-3,4-dicarboxylate;3-HYDROXYMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER;1-N-BOC-2-HYDROXYMETHYL MORPHOLINE;4-BOC-3-HYDROXYMETHYL-MORPHOLINE;N-BOC-3-hydroxymethylmorpholine;tert-Butyl 3-(hydroxymethyl)morpholine-4-carboxylate;4-Morpholinecarboxylic acid, 3-(hydroxymethyl)-, 1,1-dimethylethyl ester
• CAS NO: 473923-56-7
• Molecular Formula: C₁₀H₁₉NO₄
• Molecular Weight: 217.26
• Mol File: 473923-56-7.mol

Chemical Properties

• Boiling Point: 320.7°C at 760 mmHg
• Flash Point: 147.8°C
• Appearance: /
• Density: 1.118g/cm³
• Vapor Pressure: 2.53E-05mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: 2-8°C
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: 3-HYDROXYMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXYMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(473923-56-7)
• EPA Substance Registry System: 3-HYDROXYMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(473923-56-7)

Safety Data

• Hazardous Substances Data: 473923-56-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H19NO4/c1-10(2,3)15-9(13)11-4-5-14-7-8(11)6-12/h8,12H,4-7H2,1-3H3

Upstream product

• 212650-43-6 4-(tert-butoxycarbonyl)morpholine-3-carboxylic acid 
• 77873-76-8 morpholine-3-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 106910-83-2 (rac)-3-hydroxymethylmorpholine 
• 212650-45-8 morpholine-3,4-dicarboxylic acid 4-tert-butyl ester 3-methyl ester 
• 1269446-63-0 morpholine-3,4-dicarboxylic acid 4-tert-butyl ester 
• 106910-79-6 (RS)-4-benzyl-5-oxomorpholine-3-carboxylic acid 
• 110167-20-9 4-benzyl-3-(hydroxymethyl)morpholine 
• 955400-09-6 morpholin-3-yl methanol hydrochloride 

Downstream Products

• 1159598-86-3 4-methyl-3-(hydroxymethyl)morpholine 
• 1159598-80-7 3-[4-(4-fluorophenyl)-piperazine-1-carbonyloxymethyl]-morpholine-4-carboxylic acid tert-butyl ester 
• 1159598-91-0 3-[4-(2,4-difluoro-phenyl)-piperazine-1-carbonyloxymethyl]-morpholine-4-carboxylic acid tert-butyl ester 
• 1159598-89-6 3-(4-phenyl-piperazine-1-carbonyloxymethyl)-morpholine-4-carboxylic acid tert-butyl ester 
• 106910-83-2 (rac)-3-hydroxymethylmorpholine 
• 1620510-51-1 [(3R)-4-methylmorpholin-3-yl]methanol 
• 1398396-53-6 N-((R)-1-(naphthalen-1-yl)ethyl)-4-phenylmorpholine-3-carboxamide 
• 1398397-93-7 3-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-N-phenylmorpholine-4-carboxamide 
• 1398397-88-0 3-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-N-phenylmorpholine-4-carboxamide 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF

The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but no

TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS

The present invention provides compounds of Formula (I) as M1 receptor positive allosteric modulators for the treatment of diseases mediated by the muscarinic M1 mediator.

8-Substituted isoquinoline derivative and the use thereof

The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

PIPERAZINES AS ANTI-OBESITY AGENTS

The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds, to processes for their preparation, and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.

NEW BRADYKININ B1 ANTAGONISTS

The invention relates to compounds of formula (I), wherein R1 to R5 and X1 to X4, n and m have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The

FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of 5,6-dihydro-l,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of b.enefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Novel gamma-lactams as beta-secretase inhibitors

There is provided a series of novel substituted gamma-lactams of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4, R5 and R6 as defined herein, their ph

NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS

There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Pyrazole derivatives

This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such, the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).